3 / 8
Journal of Clinical and Molecular Endocrinology
ISSN: 2572-5432
August 09-10, 2018
Madrid, Spain
Endocrinology 2018
Page 17
11
th
International Conference on
Endocrinology and
Diabetology
D
iabetes, the scourge of mankind is an epigenetic,
progressive, inflammatory disease that affects 10 percent
of the population. Although there are genetic factors, they are
minor considering the incidence of diabetes has increased 1000
percent since 1950. What is the key, today, are the unknown
(epi-) environmental aspects. Linking xenoestrogens in the
environment to both Crohn’s Disease and Endometriosis, the
author hypothesizes the correlation exists also in adult onset
diabetes in men. The cascade is xenoestrogens cause hormonal
disruption of the Hypothalamic-Pituitary-Gonadal Axis resulting
in decrease in total testosterone (TT) production. Xenoestrogens
increase Sex-hormone-binding globulin (SHBG) further reducing
the bioavailable testosterone, measured as the Free Androgen
Index(FAI). There are three unique discoveries: Type I and Type
II diabetic men were observed; worsened disease associated
with lower FAI. Increased morbidity in the aging population
correlates inversely with FAI. All diabetic men are hypogonadal,
parenteral testosterone (not topical testosterone) has only
moderate effects on improving glycogenated hemoglobin.
Adding androlone deconate was superior to testosterone alone:
reducingglycogenated hemoglobin and areas under the curve for
glucose and insulin. Addition of a third anabolic steroid further
improved all parameters. Hypoglycemia was not a problem even
with serumglucose levels under 50mg/dl. In conclusion, diabetic
men are hypogonadal: FAI is the best biomarker measurement.
Select anabolic steroids increase FAI, testosterone, decrease
SHBG, insulin requirementsandmaximizeglucosehomeostasis..
Should physicians measure the FAI, it will serve as a starting
point for prescribing anabolic treatments, which can reverse
previously unrecognized aspects of adult onset diabetes.
Biography
Dr. Edward Mark Lichten, M.D. has graduated from Ohio State College of
Medicine as a Medical Doctor, with the specialty of Obstetrics and Gyne-
cology in1972. Later he was accepted to the Fellowship of the College of
Surgeons. He entered private practice in 1976; from there he continue his
clinical practrice, medical journal publications and his clinical research. He
has presented his research at more than 100 groups of physicians, inter-
nationally.
edwardlichten@gmail.comANABOLIC STEROIDS IN THE TREATMENT OF
DIABETES IN MEN
Edward M. Lichten
Fellow, American College of Surgeons, Fellow, American College OB-GYN
Edward M. Lichten, J Clin Mol Endocrinol 2018, Volume 3
DOI: 10.21767/2572-5432-C2-004